Evidence map›Paper›PMID 37456362›Full record

ArticleBMJ medicine2023

Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study.

Deshayne B Fell, Sheryll Dimanlig-Cruz, Eszter Török, Siri E Håberg, Annette K Regan, Jay S Kaufman, Robert W Platt, Christopher A Gravel, Liam Bruce, Prakesh S Shah and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 3 countries.

Deshayne B FellSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0002-5548-3228
Sheryll Dimanlig-CruzChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Eszter TörökChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Siri E HåbergNorwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway.
Annette K ReganSchool of Nursing and Health Professions, University of San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3879-6193
Jay S KaufmanDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Robert W PlattDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.ORCID 0000-0002-5981-8443
Christopher A GravelSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Liam BruceBetter Outcomes Registry and Network, Ottawa, ON, Canada.
Prakesh S ShahDepartment of Pediatrics, Mount Sinai Hospital, Toronto, ON, Canada.
Kumanan WilsonOttawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada.
Ann E SpragueChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Gillian D AltonChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Tavleen DhinsaChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Darine El-ChaârSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Sarah A BuchanPublic Health Ontario, Toronto, ON, Canada.
Jeffrey C KwongPublic Health Ontario, Toronto, ON, Canada.ORCID 0000-0002-7820-2046
Sarah E WilsonPublic Health Ontario, Toronto, ON, Canada.
Sandra I DunnChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Shannon E MacDonaldFaculty of Nursing, University of Alberta, Edmonton, AB, Canada.
Jon BarrettDepartment of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada.
Nannette OkunDepartment of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada.
Mark C WalkerSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
University of Ottawa · CAChildren's Hospital of Eastern Ontario · CAUniversity of Toronto · CAMcGill University · CAMcMaster University · CAMount Sinai Hospital · CANorwegian Institute of Public Health · NOOntario Stroke Network · CAUniversity of Alberta · CAUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess risk of adverse pregnancy, fetal, and neonatal outcomes after a third dose (first booster dose) of covid-19 vaccine during pregnancy among individuals who had completed both doses of primary covid-19 vaccine series before pregnancy. Design: Population based, retrospective cohort study. Setting: Ontario, Canada, from 20 December 2021 to 31 August 2022. Participants: Individuals were included if they were pregnant with an expected date of delivery from 20 December 2021 (start date of third dose eligibility for everyone ≥18 years) to 31 August 2022, who had completed the two doses of primary covid-19 messenger RNA vaccine series before pregnancy, and became eligible for a third dose (≥six months since dose two) before the end of pregnancy. Main outcome measures: Pregnancy outcomes included hypertensive disorders of pregnancy, placental abruption, caesarean delivery, chorioamnionitis, and postpartum hemorrhage. Fetal and neonatal outcomes included stillbirth, preterm birth, admission to neonatal intensive care unit for >24 h, newborn 5 min Apgar score <7, and small-for-gestational age infant (<10th percentile). We estimated hazard ratios and 95% confidence intervals for study outcomes, treating dose three as a time varying exposure and adjusting for confounding using inverse probability weighting. Results: Among 32 689 births, 18 491 (56.6%) were born to individuals who received a third covid-19 dose during pregnancy. Compared with eligible individuals who did not receive a third dose during pregnancy, no increased risks were associated with receiving a third covid-19 vaccine dose during pregnancy for placental abruption (adjusted hazard ratio 0.84 (95% confidence interval 0.70 to 1.02)), chorioamnionitis (0.67 (0.49 to 0.90)), postpartum haemorrhage (1.01 (0.89 to 1.16)), caesarean delivery (0.90 (0.87 to 0.94)), stillbirth (0.56 (0.39 to 0.81)), preterm birth (0.91 (0.84 to 0.99)), neonatal intensive care unit admission (0.96 (0.90 to 1.03)), 5 min Apgar score<7 (0.96 (0.82 to 1.14)), or small-for-gestational age infant (0.86 (0.79 to 0.93)). Conclusion: Receipt of a third covid-19 vaccine dose during pregnancy was not associated with an increased risk of adverse pregnancy, fetal, or neonatal outcomes. These findings can help to inform evidence based decision making about the risks and benefits of covid-19 booster doses during pregnancy.

Indexed as

COVID-19

Identifiers

PMID37456362
PMCPMC10347452
OpenAlexW4383874577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.